Description
CDC-Enhanced Daratumumab is a Fc-modified anti-CD38 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Daratumumab, Daratumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Multiple myeloma (MM)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD38
Full Name
CD38 Molecule
Background
CD38 (CD38 Molecule) is a Protein Coding gene.
Diseases associated with CD38 include Richter's Syndrome and Leukemia, Chronic Lymphocytic.
Among its related pathways are Cell-type Dependent Selectivity of CCK2R Signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers.
Gene Ontology (GO) annotations related to this gene include transferase activity and hydrolase activity, acting on glycosyl bonds.
An important paralog of this gene is BST1.
Gene ID
952
UniProt ID
P28907
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human IgG1, κ
Indication
Multiple myeloma (MM)
